Welcome to our dedicated page for Profusa news (Ticker: PFSA), a resource for investors and traders seeking the latest updates and insights on Profusa stock.
Profusa, Inc. (Nasdaq: PFSA) is a commercial stage digital health and medical technology company based in Berkeley, California, focused on tissue-integrated biosensors and its Lumee Oxygen tissue monitoring platform. The Profusa news feed on this page aggregates company press releases and third-party coverage related to its technology, clinical studies, commercial partnerships and capital markets activity.
Readers can expect technology and clinical news about Lumee Oxygen tissue monitoring, including study results in peripheral artery disease (PAD) and critical limb threatening ischemia (CLTI). Profusa has reported pilot phase data from a U.S.-based clinical study showing that Lumee oxygen traces strongly correlated with transcutaneous partial pressure of oxygen and that sensors remained functional for up to one year without sensor placement-related adverse events. News items also cover presentations at major vascular conferences such as Paris Vascular Insights and the Leipzig Interventional Course (LINC), where Profusa discusses additional insights into tissue oxygen monitoring.
The PFSA news stream also highlights commercial and distribution developments. Profusa has announced distributor partnerships in European markets for Lumee Oxygen tissue monitoring, including agreements intended to cover significant portions of the European Union population and to serve hospital and outpatient wound care settings. Additional releases describe collaborations with leading vascular surgeons and vascular centers in France and Greece, where Lumee technology is being adopted in clinical practice and clinical studies.
Investors will find corporate and financing updates in Profusa’s news, including details on its business combination with NorthView Acquisition Corporation, recapitalization efforts, senior secured convertible notes, and equity line of credit arrangements. The company has also outlined its own revenue targets and commercialization timelines in press releases, along with manufacturing milestones such as completion of sensor production runs and engagement of contract manufacturers for Lumee components.
By following this PFSA news page, users can track how Profusa communicates progress on its Lumee Oxygen platform, clinical validation, European commercialization plans, and balance sheet restructuring, as disclosed through its public announcements.
Profusa (Nasdaq: PFSA) reported Q2 2026 results and progress toward closing its Option Agreement to acquire G3 Vision Labs. The company highlighted that debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements, with about $4.57 million exchanged into Series A Convertible Preferred Stock.
Profusa executed a 4:1 reverse stock split effective August 18, 2026, which, together with the Option Agreement, has been supportive of meeting Nasdaq’s minimum listing requirements. Stockholders’ equity is expected to improve from a $(27.1) million deficit at June 30, 2026 to about $28.4 million as of July 31, 2026. As of June 30, cash was $719,000, total assets $1.0 million, and liabilities $28.2 million. Net loss was $(8.8) million for Q2 2026 and $(12.2) million for the first half of 2026. Profusa borrowed $650,000 for near-term working capital, and G3’s PCAOB audits for 2024 and 2025 are expected to be substantially completed by mid-September.
Profusa (Nasdaq: PFSA) has approved a 1-for-4 reverse stock split of its common stock, implemented via an amendment to its certificate of incorporation filed in Delaware. The split will take effect at 12:01 a.m. ET on August 17, 2026.
Profusa’s shares will begin trading on a post-split basis on August 17, 2026 on the Nasdaq Capital Market under the existing ticker PFSA, but with a new CUSIP 74319X405. Every four pre-split shares will be consolidated into one share, with par value unchanged at $0.0001. No fractional shares will be issued; instead, stockholders of record will receive cash in lieu of any fractional share. The reverse split will reduce shares outstanding from 2,422,906 to approximately 605,726, while authorized common shares remain at 601 million.
Profusa (Nasdaq: PFSA) signed an Option Agreement giving it the right, but not the obligation, to acquire G3 Vision Labs and subsidiaries Med Screen Laboratories, Dominion Diagnostics and Acutis Diagnostics. G3’s 2025 net revenues are estimated, based on unaudited management information, at approximately $111 million.
The option is exercisable once G3 delivers specified financial information and for 90 days thereafter, subject to conditions including at least $30 million in aggregate financings, refinancing or satisfaction of G3 indebtedness, maintenance of Profusa’s Nasdaq listing and required Nasdaq stockholder approvals. As consideration for the option, Profusa issued G3 stockholders 201,120 common shares and 52,903.566 shares of new non-voting convertible preferred stock, each convertible into 1,000 common shares upon stockholder approval. If the option is exercised, counterparties receive an additional 53,918.113 preferred shares. Entry into the Agreement does not constitute a change of control, and the securities were issued in a transaction exempt from Securities Act registration.
Profusa (Nasdaq: PFSA) signed a non-binding term sheet to acquire a privately held, commercial-stage diagnostics and toxicology testing company with estimated unaudited 2025 net revenues of about $111 million. The combined entity is expected to operate as a public diagnostics platform with national CLIA-certified labs and recurring revenue from addiction treatment, pain management, and behavioral health providers.
According to Profusa, contemplated consideration includes common stock equal to 19.99% of then-outstanding shares plus additional non-voting convertible preferred stock, with conversion subject to shareholder approval. Profusa also expects to arrange approximately $7 million of subordinated convertible note financing and exchange its outstanding convertible notes into preferred stock. Concurrently, Jack Stover has been appointed Executive Chairman and CEO, former CEO Ben Hwang becomes President, and Liviu Goldenberg joins as independent director.
Profusa (Nasdaq: PFSA) approved a 1-for-25 reverse stock split of its common stock. The split becomes effective at 12:01 a.m. ET on July 7, 2026, with trading on a post-split basis that day under ticker PFSA and new CUSIP 74319X 306.
Every 25 pre-split shares will combine into one share, with par value unchanged at $0.0001. Fractional shares will not be issued; stockholders of record receive cash instead. Outstanding shares will decline from about 13.2 million to approximately 530 thousand, while authorized shares remain 601 million.
Profusa (Nasdaq: PFSA) shareholders approved all proposals at the June 23, 2026 annual meeting. Key approvals include authorization for the planned acquisition of the PanOmics multi-omics diagnostics platform, debt conversion-related matters to strengthen the balance sheet, and a potential reverse stock split to support Nasdaq listing compliance.
Shareholders also approved a director election, an amendment to the equity incentive plan, and adjournment authority, which Profusa believes will help advance strategic initiatives, support capital structure improvements, and position the company for long-term growth.
Profusa (Nasdaq: PFSA) submitted a response package to European Notified Body GMED as part of the ongoing CE Mark review for its Lumee® Oxygen Platform. The package updates technical documentation, quality system evidence, clinical evaluation activities, and validation data under the MDR conformity process.
This follows successful completion of Stage 1 and Stage 2 assessments and aligns with Profusa’s strategy to commercialize the Lumee Oxygen Platform in Europe. The review remains in progress, with no assurance on timing or outcome.
Profusa (Nasdaq: PFSA) released a shareholder letter ahead of its June 23, 2026 annual meeting, urging investors to vote FOR all proposals.
The Board says approvals are needed to help maintain the Nasdaq listing, enable securities issuance for the PanOmics Assay asset acquisition, meet Nasdaq financing approval rules, support equity compensation, and provide flexibility to advance strategic objectives.
Profusa (Nasdaq: PFSA), a digital health company focused on continuous biochemical monitoring, announced that effective May 15, 2026, its shares are listed on The Nasdaq Capital Market.
This transfer is the first in a series of interim milestones set by a Nasdaq Hearings Panel to support continued compliance with bid price and stockholders’ equity listing requirements.
Profusa (Nasdaq: PFSA) announced that the Nasdaq Hearings Panel granted its request to transfer the listing from The Nasdaq Global Market to The Nasdaq Capital Market by letter dated May 6, 2026.
The Company’s continued Nasdaq listing is conditional on satisfying interim milestones and meeting the Capital Market bid price and stockholders' equity requirements by July 6, 2026.